 Chemical Structure.png)
NLG-1486 (IDO-IN-8) is a novel and potent indoleamine 2,3-dioxygenase (IDO) inhibitor with anticancer and immunomodulatory effects. It inhibits IDO with IC50s of <1 μM. Extracted from patent WO WO2012142237A1, compound 1486.
Physicochemical Properties
| Molecular Formula | C18H21FN2O2 |
| Molecular Weight | 316.369948148727 |
| Exact Mass | 316.158 |
| CAS # | 1402837-76-6 |
| Related CAS # | IDO-IN-5;1402837-79-9;Navoximod;1402837-78-8;IDO-IN-8;1402837-77-7 |
| PubChem CID | 70914234 |
| Appearance | White to off-white solid powder |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 555.4±35.0 °C at 760 mmHg |
| Flash Point | 289.7±25.9 °C |
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
| Index of Refraction | 1.683 |
| LogP | 1.28 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 23 |
| Complexity | 416 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | C1CC(CCC1[C@H](C[C@H]2C3=C(C=CC=C3F)C4=CN=CN24)O)O |
| InChi Key | YGACXVRLDHEXKY-VDPJLGHJSA-N |
| InChi Code | InChI=1S/C18H21FN2O2/c19-14-3-1-2-13-16-9-20-10-21(16)15(18(13)14)8-17(23)11-4-6-12(22)7-5-11/h1-3,9-12,15,17,22-23H,4-8H2/t11?,12?,15-,17-/m0/s1 |
| Chemical Name | 4-[(1S)-2-[(5S)-6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl]-1-hydroxyethyl]cyclohexan-1-ol |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | IDO-IN-6, also known as Compound 1486, is an inhibitor of indoleamine 2,3-dioxygenase (IDO) with an IC50 <1 μM, meaning that 50% of the enzyme activity concentration is inhibited by recombinant human IDO-IN-6 (International Data Organization) [1]. |
| References |
[1]. Preparation of fused imidazole derivatives as IDO inhibitors. From PCT Int. Appl. (2012), 20121018. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~50 mg/mL (~158.04 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1609 mL | 15.8043 mL | 31.6086 mL | |
| 5 mM | 0.6322 mL | 3.1609 mL | 6.3217 mL | |
| 10 mM | 0.3161 mL | 1.5804 mL | 3.1609 mL |